SDHD rs121908698: What Your Genotype Means
The rs121908698 variant is a rare genetic change located in the SDHD gene. It is associated with an autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma syndrome, a condition characterized by the development of specific neuroendocrine tumors.
What each genotype means
Typical SDHD genetic profile
This genotype represents the common, non-variant sequence for this location in the SDHD gene. It is not associated with the hereditary paraganglioma-pheochromocytoma syndrome linked to pathogenic mutations in this gene.
This is the most common genotype found in the general population.
Potential hereditary syndrome risk
This genotype indicates the presence of one copy of a variant in the SDHD gene. Inheriting such a variant can confer an autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma syndrome, though clinical expression often requires a secondary somatic mutation. You should discuss these findings with a genetic counselor or healthcare provider to understand your specific clinical risk.
This specific variant is extremely rare, with a global frequency reported at less than 0.00002 in large population databases.
Potential hereditary syndrome risk
This genotype indicates the presence of two copies of a variant in the SDHD gene. Inheriting such variants can confer an autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma syndrome, which involves an increased risk of developing neuroendocrine tumors. Please consult with a medical professional or genetic specialist to interpret the clinical significance of this result for your health.
This genotype is exceptionally rare and is not typically observed in the general population.
Understanding the Variant and Its Location
The variant rs121908698 is a specific alteration found within the SDHD gene. In genetics, an rsID (reference SNP cluster ID) acts as a unique identifier for a specific location in the human genome. The SDHD gene is situated on chromosome 11, specifically at the 11q23.1 region. This gene provides instructions for creating a protein that is a critical component of the succinate dehydrogenase (SDH) complex, which functions within the mitochondria—the energy-producing centers of our cells. When a variant occurs in this gene, it can disrupt the normal function of the SDH complex, potentially impacting how cells manage energy and signaling. Because this variant is rare, it is not typically found in the general population, and its presence is often investigated in the context of specific clinical presentations rather than routine screening.
The Role of the SDHD Gene
The SDHD gene encodes a subunit of the succinate dehydrogenase complex, also known as mitochondrial complex II. This complex plays a dual role: it is essential for the citric acid cycle, which generates energy for the cell, and it is a vital part of the electron transport chain. By anchoring the complex to the inner mitochondrial membrane, the SDHD protein ensures the stability and function of the entire assembly. Research has established that mutations in SDHD are linked to hereditary paraganglioma-pheochromocytoma syndrome type 1 (PGL1). In this syndrome, the loss of functional SDH complex activity can lead to the abnormal growth of neuroendocrine cells. These cells may form tumors known as paragangliomas, which arise from nerve tissue, or pheochromocytomas, which specifically develop in the adrenal glands. The regulation of this gene is unique due to genomic imprinting, meaning the expression of the gene can depend on whether it was inherited from the mother or the father.
Research and Clinical Associations
Scientific literature identifies the SDHD gene as a major susceptibility factor for hereditary paraganglioma and pheochromocytoma. The evidence for the pathogenicity of variants in this gene is supported by clinical observations of familial clusters of these tumors. Research indicates that inheritance follows an autosomal dominant pattern, but with a notable twist: tumors are primarily observed in individuals who inherited the variant from their father. This phenomenon is attributed to maternal imprinting, where the maternal copy of the gene is silenced. While the association between SDHD mutations and tumor risk is well-documented, the penetrance—the likelihood that a person with the variant will actually develop a tumor—is not absolute. Studies suggest that many individuals carrying such variants may not develop symptoms until the second to sixth decade of life. Because of this variability, clinical management often involves regular surveillance for those identified as carriers.
Population Frequency and Interpretation
The rs121908698 variant is extremely rare in the general population. According to data from the Genome Aggregation Database (gnomAD), the global minor allele frequency is reported to be less than 0.00002. This low frequency confirms that the variant is not a common polymorphism found in the general public but is instead a rare, clinically significant finding. Because of its rarity, most people will never encounter this variant in their genetic reports. For those who do, it is essential to understand that the presence of a variant does not constitute a medical diagnosis. Genetic testing results should always be interpreted by a qualified healthcare professional, such as a genetic counselor or a medical geneticist, who can place the finding in the context of an individual's personal and family medical history.
Navigating Genetic Information
If you or a family member have been identified as a carrier of a rare SDHD variant, the most important step is to consult with a clinical geneticist. They can provide personalized risk assessments and discuss appropriate screening protocols, such as biochemical testing or imaging, to monitor for potential tumor development. It is important to remember that genetic information is complex and should not be used for self-diagnosis. Avoid making medical decisions based solely on online reports or raw data files. Instead, use this information as a starting point for a conversation with your doctor. They can help you understand the implications of your specific genetic profile, explain the nuances of hereditary cancer syndromes, and guide you toward evidence-based management strategies that are tailored to your specific health needs and family history.
How common is this variant?
The rs121908698 variant is extremely rare, with a global minor allele frequency of less than 0.00002 in the gnomAD database.
Frequently asked questions
What is hereditary paraganglioma-pheochromocytoma syndrome?
It is an inherited condition that increases the risk of developing tumors in the adrenal glands (pheochromocytomas) or nerve tissue (paragangliomas). These tumors are often benign but can produce hormones that cause symptoms like high blood pressure.
Does having this variant mean I will get cancer?
Not necessarily. While this variant increases the risk of developing certain tumors, it does not guarantee that you will develop them. Penetrance is variable, and many carriers may remain asymptomatic for long periods.
What is genomic imprinting in the SDHD gene?
Genomic imprinting means that the activity of the gene depends on which parent passed it down. For SDHD, tumors are typically only seen when the mutation is inherited from the father, as the maternal copy is naturally silenced.
Should I get tested for this variant?
Genetic testing is usually recommended only if there is a personal or strong family history of paraganglioma or pheochromocytoma. You should discuss the necessity of testing with a genetic counselor.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908698?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29